In boon for Big Pharma, TTIP would lock in high drug prices: report | bilaterals.org
The analysis explains how expanding intellectual property rules and
monopoly protections for medicines, which the TTIP seeks to do, is
counterproductive at a time when E.U. member states and the U.S. "are
facing a looming access to medicines crisis."
